Hot on the heels of a clin­i­cal hold, Ar­row­head torch­es its clin­i­cal pipeline, slash­es staff

Just three weeks af­ter Ar­row­head Phar­ma­ceu­ti­cals $AR­WR was forced to put its lead pro­gram on clin­i­cal hold, the biotech is torch­ing every­thing re­lat­ed to its EX1 de­liv­ery ve­hi­cle, wip­ing out three RNAi treat­ments — all of its clin­i­cal-stage work — and elim­i­nat­ing close to a third of its staff in a re­or­ga­ni­za­tion.

The un­ex­pect­ed news, which stunned a few an­a­lysts on Tues­day evening, elim­i­nates its ARC-520, ARC-521 and ARC-AAT ef­forts. Its stock was evis­cer­at­ed, los­ing 60% of its val­ue on the news.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER